share_log
Breakings ·  May 24 04:08
Supernus Pharmaceuticals Inc: Spn-817 Discontinuation Rate Due to Adverse Events (AES) of 22% in Titration Period and 2.4% in Maintenance Period
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment